IUL Study A Randomized Sham - Controlled Clinical Study

Stress Urinary Incontinence Clinical Trial

Official title:

Intraurethral Laser Therapy for Stress Urinary Incontinence: A Randomized Sham - Controlled Clinical Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04707690
• Other study ID #: V1
• Status: Recruiting
• Phase: N/A
• Start date: January 8, 2021
• Est. completion date: January 1, 2025

Study information

• Verified date: January 2024
• Source: Medical University of Graz
• Contact: Daniela Gold, MD PhD
• Phone: 0043316 385 81437
• Email: daniela.gold[@]medunigraz.at
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Primary aim of the study is to compare the impact of SUI on the VAS (visual analogue scale) 3 months after laser therapy versus sham laser therapy.

Description:

Background: Stress urinary incontinence (SUI) has a huge impact on the quality of life (QoL) in women and its treatment is challenging. Intraurethral laser may be an additional treatment option.

Study aim: The aim is to study the effectiveness of intraurethral laser therapy in women with SUI.

Design: randomized double blinded sham - controlled clinical study

Study population: women which have been diagnosed with SUI I-II°, aged between 18-80 years.

Study groups: Participants will be randomized (1:1), without stratification. The Intervention group will receive 2 treatments of intraurethral laser therapy and the Control group will receive 2 treatments of intraurethral SHAM laser therapy.

Sample size: A sample size of 20 women, 8 per group including a 20% Drop Out Rate, was calculated.

Primary outcome: impact of SUI on the VAS scale 3 months after laser therapy versus sham laser therapy.

Secondary study outcomes were defined as subjective SUI, objective SUI, QoL, treatment satisfaction, intraurethral microbiome, 3 months after laser therapy versus sham laser therapy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: January 1, 2025
• Est. primary completion date: January 1, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Female between 18 and 80 years

• Confirmed SUI through cough stress test within the last 24 months

• SUI I-II° for more than 6 months

• At least one incontinence episode per 24 hour period measured over three days according to a bladder diary

• Valsalva leak-point pressure (VLPP) =60 cm H2O

• Maximum cystometric capacity =250 mL

• No pelvic surgery within last 6 months (including prolapse repair, subjects who have residual or recurrent SUI following colposuspension or a sling procedure may be included in the study if the procedure was conducted at least 6 months prior to screening /baseline visit)

• BMI (body mass index) =35 kg/m2

• Willing to give informed consent and complete the follow up schedule

Exclusion Criteria:

• Active lower urinary tract infections (urethritis, cystitis or vaginitis)

• Three (3) or more cultured-proven bacterial urinary tract infection (UTI) in the last 12 months

• Detrusor overactivity on urodynamics

• Postvoiding residual (PVR) > 100 ml

• Previous urethral surgery (i.e. fistula or diverticula)

• Pelvic organ prolapse grade > 3 as defined by POP-Q and symptomatic

• Known polyuria (>3l/24h)

• Unevaluated macro hematuria

• Neurogenic bladder

• Evidence of dysplasia in a Pap smear (done in the last 24 months)

• Tumours of the Urinary tract

• Previous radiation or brachytherapy to treat pelvic cancer

• Uncontrolled diabetes

• Active herpes genitalis

• Pregnancy

• Vaginal delivery within 6 months prior to the Screening/Baseline Visit

Related Conditions & MeSH terms

• Enuresis
• Stress Urinary Incontinence
• Urinary Incontinence
• Urinary Incontinence, Stress

Intervention

Device:
• Intraurethral laser therapy
The laser will be applied according to the manufacturer's protocol. This includes a 2 step laser treatment using 2 different modes at 2 timepoints. The treatment takes about 15 minutes time.
• Intraurethral SHAM laser therapy
The laser will be applied according to the manufacturer's protocol. This includes a 2 step laser treatment using 2 different modes at 2 timepoints. The treatment takes about 15 minutes time.

Locations

Country	Name	City	State
Austria	Departement of Obstetrics and Gynecology	Graz	Styria

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Graz

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Subjective symptoms of SUI	A visual analogue scale (VAS) is used for assessment for the subjective symptoms and improvement of SUI. Patients are asked to indicate the degree of their symptoms on a scle ranging from 0 (no symptoms) to 10 (worst possible symptoms).	3 months
Secondary	Degree of pain during laser therapy on a visual analogue scale (VAS)	Patients are asked to indicate the degree of pain during laser therapy on a visual analogue scale (VAS) ranging from 0 (no pain) to 10 (worst possible pain).	3 months
Secondary	Subjective SUI	Subjective SUI as determined by the question "do you leak urine when coughing, sneezing or laughing" with the answer possibilities of "Yes" and "No".	3 months
Secondary	Objective SUI	Objective SUI as determined by the cough stress test at 300ml bladder filling, which will either be positive or negative.	3 months
Secondary	Patient Global Impression of Improvement	The PGI-I scales are robust and valid instruments to assess disease severity, bother and improvement after treatment in women and will be used to determine the Patient Global Impression of Improvement. The PGI-I consists of a 7-likert-scale with 7 being the worst bother.	3 months
Secondary	Patient Global Impression of Severity	The Patient Global Impression of Severity (PGI-S) is a global index that may be used to rate the severity of a specific condition (in a single-state scale). The PGI-I scales are robust and valid instruments to assess disease severity, bother and improvement after treatment in women and will be used to determine the Patient Global Impression of Severity. The PGI scales are robust and valid instruments to assess disease severity, bother and improvement after treatment. The patient can choose from 4 answers including none, mild, moderate and severe.	3 months
Secondary	Quality of Life using the Kings Health Questionnaire	The Kings Health Questionnaire was validated in women with stress urinary incontinence and assesses the impact of incontinence on quality of life. The eight subscales ("domains") scored between 0 (best) and 100 (worst). The Symptom Severity scale is scored from 0 (best) to 30 (worst); lower scores indicate better QoL. Success in terms of the study is defined as 10 points improvement on the total Kings Health Questionnaire score.	3 months
Secondary	Pelvic floor symptoms	A validated self-administered pelvic floor questionnaire (Baessler) will be used to assess urogentinal symptoms. Questions regarding bladder (15), bowel (12), and sexual function (10), and pelvic organ prolapse symptoms (five) are grouped according to the physiological functions of the pelvic floor: bladder function, bowel function, prolapse symptoms, and sexual function domains. Quality of life measures and bothersomeness ratings were integrated into the four domains. Frequency, severity, and bothersomeness of pelvic floor symptoms are assessed using a four-point scoring system for most items in the questionnaire, apart from defecation frequency, bowel consistency, sufficient lubrication, and the reason for sexual abstinence. The lower the score the less pelvic floor symptoms the patients have.	3 months
Secondary	Pad Weight	In regards to the one-hour stress pad weight test women are asked to drink 500 ml of sodium-free liquid in <15 min, then sit, walk for 30 min including climbing one flight of stairs. Afterwards the total amount of urine leaked is determined by weighing the pad. Lower weight means less urine loss.	3 months
Secondary	Patient satisfaction with treatment/inpatient management	Patient satisfaction will be evaluated with the "Fragebogen zur Patientenzufriedenheit - ZUF-8". The German version of the original "Client Satisfaction Questionnaire-CSQ8", is a validated tool for measuring global patient satisfaction at the end of inpatient treatment. The ZUF-8 is an 8-items questionnaire to assess satisfaction in patients undergoing inpatient treatment. At 3 months treatment satisfaction will be assessed using an adopted version of the questionnaire. The lower the score, the higher is the patient satisfaction.	3 months
Secondary	Microbiome	Extraction of archaeal/bacterial 16S rRNA gene using the Illumina MiSeq platform in order to determine the intraurethral microbiome	3 months